{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:53:59Z","timestamp":1777013639259,"version":"3.51.4"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T00:00:00Z","timestamp":1550620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0211228","type":"journal-article","created":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T18:30:28Z","timestamp":1550687428000},"page":"e0211228","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":149,"title":["Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2520-5673","authenticated-orcid":true,"given":"Daniel","family":"Caldeira","sequence":"first","affiliation":[]},{"given":"Daniela","family":"Alves","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Joaquim J.","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Fausto J.","family":"Pinto","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2019,2,20]]},"reference":[{"issue":"10","key":"ref1","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"JR Brown","year":"2017","journal-title":"Haematologica"},{"issue":"9989","key":"ref2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0140-6736(14)61774-8","article-title":"50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study","volume":"386","author":"RB Schnabel","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40264-017-0586-2","article-title":"Cardiac Harms of Sofosbuvir: Systematic Review and Meta-Analysis","volume":"41","author":"D Caldeira","year":"2018","journal-title":"Drug Saf"},{"issue":"7","key":"ref4","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1136\/heartjnl-2013-305288","article-title":"Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis","volume":"100","author":"D Caldeira","year":"2014","journal-title":"Heart"},{"issue":"1","key":"ref5","first-page":"41","article-title":"Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE","volume":"94","author":"SS Wong","year":"2006","journal-title":"J Med Libr Assoc"},{"issue":"2","key":"ref6","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"JM Glanville","year":"2006","journal-title":"J Med Libr Assoc"},{"issue":"11","key":"ref7","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/europace\/euw295","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"18","author":"P Kirchhof","year":"2016","journal-title":"Europace"},{"key":"ref8","unstructured":"Health CTEP-DoCTaDNIo. Common Terminology Criteria for Adverse Events (CTCAE) [December 2018]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_archive\" xlink:type=\"simple\">https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_archive<\/ext-link>."},{"key":"ref9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"J IntHout","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1081\/BIP-200067915","article-title":"A note on variance estimation in random effects meta-regression","volume":"15","author":"K Sidik","year":"2005","journal-title":"J Biopharm Stat"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1002\/jrsm.1319","article-title":"Methods to calculate uncertainty in the estimated overall effect size from a random-effects meta-analysis","author":"AA Veroniki","year":"2018"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"JP Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jrsm.1230","article-title":"Basics of meta-analysis: I(2) is not an absolute measure of heterogeneity","volume":"8","author":"M Borenstein","year":"2017","journal-title":"Res Synth Methods"},{"issue":"7","key":"ref14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"J IntHout","year":"2016","journal-title":"BMJ Open"},{"issue":"7109","key":"ref15","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"M Egger","year":"1997","journal-title":"Bmj"},{"key":"ref16","unstructured":"Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0: The Cochrane Collaboration; 2011."},{"issue":"7454","key":"ref17","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"D Atkins","year":"2004","journal-title":"Bmj"},{"issue":"4","key":"ref18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"H Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"JC Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"ref20","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","volume":"373","author":"JA Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"ref21","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","volume":"17","author":"A Chanan-Khan","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10020","key":"ref22","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"M Dreyling","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"ref23","first-page":"1043","article-title":"Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study","volume":"7","author":"X Huang","year":"2018","journal-title":"Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study"},{"issue":"25","key":"ref24","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom&apos;s Macroglobulinemia","volume":"378","author":"MA Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL","author":"JA Woyach","year":"2018"},{"key":"ref26","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","author":"C Moreno","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"ref27","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41375-018-0023-2","article-title":"Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study","volume":"32","author":"S Rule","year":"2018","journal-title":"Leukemia"},{"key":"ref28","unstructured":"Summary of Product Characteristics\u2014Imbruvica (Ibrutinib) 2018 [11.10.2018]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.ema.europa.eu\/documents\/product-information\/imbruvica-epar-product-information_en.pdf\" xlink:type=\"simple\">https:\/\/www.ema.europa.eu\/documents\/product-information\/imbruvica-epar-product-information_en.pdf<\/ext-link>."},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood-2016-05-712828","article-title":"The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis","volume":"128","author":"DP Leong","year":"2016","journal-title":"Blood"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clml.2016.09.010","article-title":"Risk of Atrial Fibrillation and Bleeding Diathesis Associated With Ibrutinib Treatment: A Systematic Review and Pooled Analysis of Four Randomized Controlled Trials","volume":"17","author":"S Yun","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"ref31","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1080\/10428194.2016.1257795","article-title":"Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)","volume":"58","author":"TD Shanafelt","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"9735","key":"ref32","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0140-6736(10)60834-3","article-title":"Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study","volume":"376","author":"MJ O'Donnell","year":"2010","journal-title":"Lancet"},{"issue":"7\u20138","key":"ref33","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.repc.2016.12.012","article-title":"The era of the novel oral anticoagulants in Portugal","volume":"36","author":"D Caldeira","year":"2017","journal-title":"Rev Port Cardiol"},{"issue":"1","key":"ref34","first-page":"1","article-title":"Burden of disease and cost of illness of atrial fibrillation in Portugal","volume":"34","author":"M Gouveia","year":"2015","journal-title":"Rev Port Cardiol"},{"issue":"25","key":"ref35","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"JR McMullen","year":"2014","journal-title":"Blood"},{"issue":"2","key":"ref36","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/10428194.2017.1339874","article-title":"Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management","volume":"59","author":"BC Thorp","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"ref37","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1182\/blood-2015-01-621466","article-title":"Response: Additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinib","volume":"125","author":"JC Byrd","year":"2015","journal-title":"Blood"},{"issue":"7","key":"ref38","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacc.2014.11.046","article-title":"Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?","volume":"65","author":"TF Chao","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"ref39","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jacc.2015.01.044","article-title":"Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score","volume":"65","author":"GY Lip","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"ref40","first-page":"CD004937","article-title":"[What is the benefit of salt reduction on blood pressure? Assessment of the Cochrane Review: Effect of longer-term modest salt reduction on blood pressure","volume":"4","author":"D Caldeira","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"ref41","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.acvd.2011.11.005","article-title":"Rate versus rhythm control in atrial fibrillation and clinical outcomes: updated systematic review and meta-analysis of randomized controlled trials","volume":"105","author":"D Caldeira","year":"2012","journal-title":"Arch Cardiovasc Dis"},{"issue":"5","key":"ref42","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ejim.2011.05.001","article-title":"Rate vs rhythm control in patients with atrial fibrillation and heart failure: a systematic review and meta-analysis of randomised controlled trials","volume":"22","author":"D Caldeira","year":"2011","journal-title":"Eur J Intern Med"},{"issue":"3","key":"ref43","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s00415-014-7462-0","article-title":"Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis","volume":"262","author":"D Caldeira","year":"2015","journal-title":"J Neurol"},{"issue":"4","key":"ref44","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s40256-015-0132-5","article-title":"Tolerability and Acceptability of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation: Systematic Review and Meta-Analysis","volume":"15","author":"D Caldeira","year":"2015","journal-title":"Am J Cardiovasc Drugs"},{"issue":"4","key":"ref45","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40256-014-0071-6","article-title":"Dyspnea and reversibility profile of P2Y(1)(2) antagonists: systematic review of new antiplatelet drugs","volume":"14","author":"D Caldeira","year":"2014","journal-title":"Am J Cardiovasc Drugs"},{"issue":"5","key":"ref46","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/jth.12544","article-title":"Efficacy and safety of low molecular weight heparin in patients with mechanical heart valves: systematic review and meta-analysis","volume":"12","author":"D Caldeira","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"7","key":"ref47","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/pds.3791","article-title":"Risk of renal failure with the non-vitamin K antagonist oral anticoagulants: systematic review and meta-analysis","volume":"24","author":"D Caldeira","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0211228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T06:49:59Z","timestamp":1589006999000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0211228"}},"subtitle":[],"editor":[{"given":"Ralf","family":"Bender","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2019,2,20]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0211228","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,20]]}}}